Zentalis Pharmaceuticals stock: azenosertib data sharpen biomarker case

Zentalis Pharmaceuticals presented updated overall-survival data for azenosertib at the European Society for Medical Oncology Congress in Madrid on Friday, October 23, 2026. The results came from an interim analysis of the DENALI Part 1b study in platinum-resistant ovarian cancer.

According to Zentalis Pharmaceuticals, the May 22, 2026 data cutoff covered 102 patients who had received between one and five prior treatment lines and had previously received bevacizumab. In the Cyclin E1-positive subgroup, median overall survival reached 15.9 months, compared with 7.5 months in the Cyclin E1-negative subgroup.

Biomarker guides late-stage program

The interim analysis also showed an objective response rate of 37.2 percent among response-evaluable Cyclin E1-positive patients and 33.3 percent across the full Cyclin E1-positive group. Median duration of response was 5.5 months.

The treatment profile remains an important consideration. Treatment-related adverse events led to dose interruptions in 56.9 percent of patients, dose reductions in 43.1 percent and discontinuation in 19.6 percent. Serious treatment-related adverse events occurred in 21.6 percent of patients.

Zentalis is using the findings to support further development of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer. DENALI Part 2 and the ASPENOVA Phase 3 confirmatory trial are the next major development steps.

What Zentalis Pharmaceuticals does

Zentalis Pharmaceuticals is a U.S.-based clinical oncology company developing oral, non-chemotherapy treatments guided by biomarkers. Its lead program is azenosertib, an investigational WEE1 inhibitor being studied as a monotherapy and in combination studies for ovarian cancer and other tumor types. The company is focused on translating WEE1 biology into targeted cancer treatment.

At this stage, Zentalis is a specialized development-stage oncology company rather than a commercial pharmaceutical group with an established marketed portfolio. Its position depends on clinical execution, biomarker selection and progress toward potential registration.

The broader U.S. equity market remains the relevant backdrop for Zentalis Pharmaceuticals stock; investors can follow current S&P 500 market reports.

For more company-specific developments, see the real-time quote of Zentalis Pharmaceuticals stock and more news and analyses on Zentalis Pharmaceuticals stock.